- Formulife, Inc.
- Issuing Office:
Office of Human &Animal Food Operations, West Division 3
March 2, 2018
Brandon M. Smith, Owner and President
Purus Labs, Inc.
1253 Andrews Parkway
Allen, Texas 75002-2692
Dear Mr. Smith:
The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letters (2012-DAL-WL-12, January 18, 2012; 2013-DAL-WL-38, June 17, 2013; and 2017-DAL-WL-21, May 12, 2017). Based on our evaluation, it appears that you have addressed the violations contained in these Warning Letters. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Chad J. Whitwell
Acting Director, Compliance Branch
Human & Animal Food Operations, WD3